Massive tuberculous exudative pericarditis under the guise of hydropericardium in a patient with non-compaction cardiomyopathy: diagnosis and treatment
https://doi.org/10.15829/1560-4071-2019-11-55-62
Abstract
The first presentation of the combination of non-compaction cardiomyopathy with a restrictive-dilated phenotype and massive chronic tuberculous pericarditis, which for a long time was under the guise of hydropericardium in congestive heart failure in a patient of 30 years, is performed. The absence of congestion signs in a large circle of blood circulation became the reason for diagnosis of agnogenic pericarditis and pericardial puncture. A large volume (>1 l) and lymphocytic nature of effusion, its bilateral character, post-tuberculous changes and calcifications in the lungs, and intrathoracic lymphadenopathy testified in favor of the tuberculous etiology of the process. The negative result of all laboratory tests for tuberculosis (Diaskintest, exudate PCR test, fluorescence microscopy, inoculation on liquid media, Ziehl-Neelsen stain) and the high risk of thoracoscopic biopsy did not allow to immediately verify the diagnosis. It was made only after repeated elimination of 3,5 l of hemorrhagic exudate and the detection of mycobacterial DNA by PCR. As a result of quadruple tuberculostatic therapy, a remission of the process was achieved (there is no fluid in the pericardial cavity).
About the Authors
O. V. BlagovaRussian Federation
Moscow.
I. N. Alieva
Russian Federation
Moscow.
P. V. Senchikhin
Russian Federation
Moscow.
L. D. Nazarova
Russian Federation
Moscow.
S. V. Chernyavsky
Russian Federation
Moscow.
G. Yu. Sorokin
Russian Federation
Moscow.
E. V. Pavlenko
Russian Federation
Moscow.
V. P. Sedov
Russian Federation
Moscow.
N. V. Gagarina
Russian Federation
Moscow.
N. D. Sarkisova
Russian Federation
Moscow.
References
1. Adler Y, Charron P, Imazio M, et al; European Society of Cardiology (ESC). 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36(42):2921-64. doi:10.1093/eurheartj/ehv318.
2. Gouriet F, Levy PY, Casalta JP, et al. Etiology of Pericarditis in a Prospective Cohort of 1162 Cases. Am J Med. 2015;128(7):784.e1-8. doi:10.1016/j.amjmed.2015.01.040.
3. Maisch B, Rupp H, Ristic A, Pankuweit S. Pericardioscopy and epi- and pericardial biopsy — a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Fail Rev. 2013;18(3):317-28. doi:10.1007/s10741-013-9382-y.
4. Yadav S, Singh M, Singh P, et al. Cytological evaluation of pericardial fluids: A 5 years experience in tertiary care center. Indian J Pathol Microbiol. 2019; 62(2):270-3. doi:10.4103/IJPM.IJPM_360_18.
5. Noubiap JJ, Agbor VN, Ndoadoumgue AL, et al. Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart. 2019 Feb;105(3):180-8. doi:10.1136/heartjnl-2018-313922.
6. Dyomin AA, Drobysheva VP. Pericardium diseases. Russian Journal of Cardiology. 2016;(1):90-8. (In Russ.) doi:10.15829/1560-4071-2016-1-90-98.
7. Kasifoglu T, Cavusoglu Y, Korkmaz C, Birdane A. Noncompaction of the ventricular myocardium in a patient with Behçet’s disease showing multiple thrombus formations in the right atrium, inferior vena cava and right iliac vein: A case report. Int J Angiol. 2007;16(2):69-72.
8. Blagova OV, Pavlenko EV, Varionchik NV, et al. Myocarditis as a legitimate phenomenon in non-compaction myocardium: diagnostics, management and influence on outcomes. Russian Journal of Cardiology. 2018;(2):44-52. (In Russ.) doi:10.15829/1560-4071-2018-2-44-52.
9. Mayosi BM, Wiysonge CS, Ntsekhe M. Mortality in patients treated for TB pericarditis in sub-Saharan Africa. S. Afr. Med. J. 2008;98:36-40. doi:10.5830/CVJA-2016-035.
10. Lazaros G, Antonopoulos AS, Imazio M, et al. Clinical significance of pleural effusions and association with outcome in patients hospitalized with a first episode of acute pericarditis. Intern Emerg Med. 2019 Mar 13. doi:10.1007/s11739-019-02041-3.
11. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014; 383(9936):2232-7.
12. Liebenberg JJ, Dold CJ, Olivier LR. A prospective investigation into the effect of colchicine on tuberculous pericarditis. Cardiovasc J Afr. 2016;27(6):350-5. doi:10.5830/CVJA-2016-035.
Review
For citations:
Blagova O.V., Alieva I.N., Senchikhin P.V., Nazarova L.D., Chernyavsky S.V., Sorokin G.Yu., Pavlenko E.V., Sedov V.P., Gagarina N.V., Sarkisova N.D. Massive tuberculous exudative pericarditis under the guise of hydropericardium in a patient with non-compaction cardiomyopathy: diagnosis and treatment. Russian Journal of Cardiology. 2019;(11):55-62. (In Russ.) https://doi.org/10.15829/1560-4071-2019-11-55-62